Accordingly, a study reported that omipalisib (GSK2126458), an inhibitor of PI3K-mTOR, was under Phase I clinical trial in the treatment of IPF (Lukey et al., 2019). The gene discussed is MTOR; the disease is idiopathic pulmonary fibrosis.